Article

Planning influenza vaccination programs: a cost benefit model

Clinical Outcomes & Analytic Services, Walgreens Co,, 1415 Lake Cook Rd,, MS L444, Deerfield, IL, 60015, USA. .
Cost Effectiveness and Resource Allocation (Impact Factor: 0.87). 07/2012; 10(1):10. DOI: 10.1186/1478-7547-10-10
Source: PubMed

ABSTRACT

Although annual influenza vaccination could decrease the significant economic and humanistic burden of influenza in the United States, immunization rates are below recommended levels, and concerns remain whether immunization programs can be cost beneficial. The research objective was to compare cost benefit of various immunization strategies from employer, employee, and societal perspectives.
An actuarial model was developed based on the published literature to estimate the costs and benefits of influenza immunization programs. Useful features of the model included customization by population age and risk-level, potential pandemic risk, and projection year. Various immunization strategies were modelled for an average U.S. population of 15,000 persons vaccinated in pharmacies or doctor's office during the 2011/12 season. The primary outcome measure reported net cost savings per vaccinated (PV) from the perspective of various stakeholders.
Given a typical U.S. population, an influenza immunization program will be cost beneficial for employers when more than 37% of individuals receive vaccine in non-traditional settings such as pharmacies. The baseline scenario, where 50% of persons would be vaccinated in non-traditional settings, estimated net savings of $6 PV. Programs that limited to pharmacy setting ($31 PV) or targeted persons with high-risk comorbidities ($83 PV) or seniors ($107 PV) were found to increase cost benefit. Sensitivity analysis confirmed the scenario-based findings.
Both universal and targeted vaccination programs can be cost beneficial. Proper planning with cost models can help employers and policy makers develop strategies to improve the impact of immunization programs.

  • Source

    Full-text · Article · Oct 2012 · The Journal of Infectious Diseases
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: AbStRACt Background: In the past decade the upsurge of influenza throughout the globe was significant and in recent years this has resurfaced showing failures of all the preventive and therapeutic measures against it. Thus, this study was undertaken to evaluate the effect of homoeopathic medicines in the treatment of Influenza like illness (primary objective) and to compare the complication rate among patients receiving homoeopathic medication as compared to the patients receiving placebo and also to compare the efficacy of LM potency vis-à-vis Centesimal potency (secondary objective). Material and Methods: This was a multicenter, prospective, randomized, triple arm placebo controlled trial conducted at nine Institutes and Units of Central Council for Research in Homoeopathy (CCRH) from June 2009 to December 2010. The patients fulfilling the inclusion criteria were randomized to LM, Centesimal and Placebo groups. Homoeopathic interventions were given as per the principles of homoeopathy. Symptoms of Influenza like illness (ILI) were assessed as per validated scales. Data analysis was done using statistical package of SPSS 20.0 version. Each symptom was compared for 10 days among the allocated groups by using Kruskal wallis test and bonferroni correction for the multiple comparisons. Results: Out of 739 screened cases, 447 cases were eligible for enrolment comprising of LM (n=152), (n=147) and placebo (n=148) cases. There was a significant difference in temperature from 2 nd
    Full-text · Article · Mar 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although vaccination rates in children exceed 90% in the United States, adults are vaccinated at far lower rates. In order to address this issue, additional community immunizers are needed, and pharmacists are in an ideal position to fill this void. To explore issues and barriers related to implementation of a pharmacy-based adult vaccine benefit and develop recommendations supporting a pathway for benefit expansion. A literature review on the current environment surrounding pharmacy-based adult vaccinations and structured interviews were conducted to inform an expert panel meeting using a modified Delphi process (pre/post survey). The goal was to develop recommendations on how to improve access to adult vaccines. Findings suggest employers play a key role in requesting changes in benefit design to include pharmacy-based vaccinations. However, the lack of consistent communication between pharmacists and primary care providers remains a significant barrier. Pharmacy-based access to vaccinations improves patient access and benefits individuals and employers. In order to take advantage of this opportunity, pharmacists must be viewed within the broader context of preventative care, including pharmacy-based vaccinations.
    No preview · Article · Mar 2014 · Journal of managed care pharmacy: JMCP